While the proposed changes to the Medicare Shared Savings Program (MSSP) won’t mean a large number of changes to Coastal Carolina Quality Care, the accountable care organization will have to make some changes to respond to the new Enhanced track, said Stephen Nuckolls, CEO of Coastal Carolina Quality Care.
While the proposed changes to the Medicare Shared Savings Program (MSSP) won’t mean a large number of changes to Coastal Carolina Quality Care, the accountable care organization will have to make some changes to respond to the new Enhanced track, said Stephen Nuckolls, CEO of Coastal Carolina Quality Care.
Transcript
Coastal Carolina Quality Care has been participating in the MSSP since the beginning. What do the proposed changes mean for your ACO?
There were a number of different changes in the Pathways to Success. We are currently looking at Track 3 for next year or, under the new proposed regulations, would be called the Enhanced track. There were not a great number of changes to it. There was 1 with benchmarking, where they would allow the benchmark to go up by 3% for risk adjustment. So, we see that as a positive. While we would like for it to be more than 3%, just the acknowledgement that the population does change over time and they are allowing for some upward fluctuation, as well as downward fluctuation, in the risk scores, we see as a positive.
Has the ACO started identifying how it might need to change if the Pathways to Success regulations take effect?
With the new proposed Pathways to Success, we are considering a Track 3 ACO or Enhanced track for next year. As part of that, to get ready, we’re doing a number of things. We’re evaluating an aggregate reinsurance contract, because the risk of substantial loss to a small medical practice is big. So, we’re looking at those options. Largely, we will be using a lot of the same techniques that we’ve used in the past. It is a much greater risk, but with that risk will also come some anxiety, and maybe that will lead to greater performance. But we’ll just have to see.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More